Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bortezomib Booms For Stada As Russian Problem Remains

Turnaround Strategy Is In The Works In Russia

Executive Summary

With group sales rising by double digits in 2019, Stada says it has the firepower to accelerate investment not only in the firm’s own product development but also broadly into external co-development and product in-licensing, to support sustainability and long-term growth.

You may also be interested in...



Stada Adds To Consumer Business With Sanofi Deal

Stada has expanded its business with another acquisition in the consumer healthcare space, this time striking a deal with Sanofi for 16 brands across 13 European markets.

Stada Raises Sales And Earnings But Admits ‘Tough’ Q2

Privately-owned Stada provided little insight into the exact mechanics of its operations for the first six months of 2020 but nevertheless said it had enjoyed an “above-market sales and earnings increase.” However, a raft of one-off expenses bit into the German firm’s profitability.

Stada Will Continue To Invest To Drive Growth

After a 12-month period that has seen Stada make significant investments in generics, biosimilars and consumer healthcare, CEO Peter Goldschmidt tells Generics Bulletin that the firm does not intend to stop there, as it pursues both organic and inorganic growth opportunities.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB149713

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel